CONFERENCE PROGRAM

Friday, July 19

5:00 p.m.-7:00 p.m. OPENING KEYNOTE LECTURES
Grand Ballroom A

Next-generation CAR T cells
Crystal Mackall, Stanford University, Stanford, CA

A path towards successful T-cell therapy for solid cancers
Patrick Hwu, The University of Texas MD Anderson Cancer Center, Houston, TX

7:00 p.m.-9:00 p.m. OPENING RECEPTION
Grand Ballroom BC

Saturday, July 20

7:00 a.m.-8:00 a.m. BREAKFAST
Grand Ballroom BC

8:00 a.m.-10:00 a.m. PLENARY SESSION 1: CELLULAR THERAPY CLINICAL UPDATES (I)
Grand Ballroom A
Session Chair: Christine E. Brown, City of Hope National Medical Center, Duarte, CA

8:00 a.m.-8:30 a.m. Chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia
Saar Gill, University of Pennsylvania, Philadelphia, PA

8:30 a.m.-9:00 a.m. CAR-T antigen evasion: The emerging role for multtargeted CAR therapy
David B. Miklos, Stanford University, Stanford, CA

9:00 a.m.-9:30 a.m. Advancing CAR T cells for the treatment of brain tumors
Christine E. Brown

9:30 a.m.-9:45 a.m. Targeting pancreatic cancer using nonengineered, multiantigen-specific T cells (TACTOPS)*
Brandon G. Smaglo, Baylor College of Medicine, Houston, TX
Cellular immunomonitoring for the first personalized adoptive cellular therapy trial using defined multiple targets (ACTolog® IMA101-101)*
Anna Nowak, Immatics Biotechnologies GmbH, Tübingen, Germany

10:00 a.m.-10:30 a.m.  BREAK
Grand Ballroom Foyer

10:30 a.m.-12:30 p.m.  PLENARY SESSION 2: CAR T-CELL ENGINEERING—BARRIERS FOR TARGETING SOLID TUMORS
Grand Ballroom A
Session Chair: Philip D. Greenberg, Fred Hutchinson Cancer Research Center, Seattle, WA

10:30 a.m.-11:00 a.m.  Engineering lymphocytes for the adoptive immunotherapy of solid tumors
Stephen Gottschalk, St. Jude Children’s Research Hospital, Memphis, TN

11:00 a.m.-11:30 a.m.  Molecular and epigenetic programs defining tumor-specific T-cell dysfunction and therapeutic reprogrammability
Andrea Schietinger, Memorial Sloan Kettering Cancer Center, New York, NY

11:30 a.m.-12:00 p.m.  Engineering T cells to eradicate tumors: It starts with the TCR but doesn’t stop there
Philip D. Greenberg

12:00 p.m.-12:15 p.m.  HER2-specific chimeric antigen receptor T cells with NKILA knockout improves therapeutic effects towards HER2+ breast cancer*
Erwei Song, Sun Yat-sen University, Guangzhou, China

12:15 p.m.-12:30 p.m.  Regulation of CD40L on chimeric antigen receptor T cells enhances immune function translating to antitumor effects*
Michelle Fleury, Obsidian Therapeutics, Cambridge, MA

12:30 p.m.-2:30 p.m.  LUNCH / POSTER SESSION A
Grand Ballroom BC

2:30 p.m.-4:00 p.m.  PLENARY SESSION 3: SCALABILITY OF T-CELL THERAPY—DRIVING DOWN COSTS
Grand Ballroom A
Session Chair: Barbra J. Sasu, Allogene Therapeutics, San Francisco, CA
2019 AACR Special Conference on Immune Cell Therapies for Cancer: Successes and Challenges of CAR T Cells and Other Forms of Adoptive Therapy

2:30 p.m.-3:00 p.m.  Allogene: Leading the next revolution in cell therapy  
Barbra J. Sasu

3:00 p.m.-3:30 p.m.  Scalability of T-cell therapy  
Gwen Binder-Scholl, Cabaletta Bio Inc., Philadelphia, PA

3:30 p.m.-4:00 p.m.  Innovating and planning our way to improve affordability and accessibility for chimeric antigen receptor (CAR) T-cell therapies  
Heidi Zhang, Celgene Corp., San Francisco, CA

4:00 p.m.-4:30 p.m.  BREAK  
Grand Ballroom Foyer

4:30 p.m.-6:30 p.m.  PLENARY SESSION 4: NK AND OTHER IMMUNE CELL THERAPIES  
Grand Ballroom A  
Session Chair: Catherine M. Bollard, Children’s National Health System, Washington, DC

4:30 p.m.-5:00 p.m.  Off-the-shelf, CAR-engineered, cord blood–derived NK cells for the treatment of cancer  
Katy Rezvani, The University of Texas MD Anderson Cancer Center, Houston, TX

5:00 p.m.-5:30 p.m.  TGFβ-resistant T and NK cells for cancer  
Catherine M. Bollard

5:30 p.m.-6:00 p.m.  Selective expansion of adaptive natural killer cells for cancer immunotherapy  
Karl-Johan Malmberg, The University of Oslo, Oslo, Norway

6:00 p.m.-6:15 p.m.  ACTR and BOXR T-cell therapies: Addressing the challenges of solid tumors*  
Heather Huet, Unum Therapeutics, Cambridge, MA

6:15 p.m.-6:30 p.m.  Targeting the chemokine receptor CCR4 using chimeric antigen receptor T cells for the treatment of CCR4+ T-cell malignancies*  
Marissa Del Real, City of Hope, Duarte, CA

6:30 p.m.  DINNER ON OWN

Sunday, July 21
2019 AACR Special Conference on Immune Cell Therapies for Cancer: Successes and Challenges of CAR T Cells and Other Forms of Adoptive Therapy

7:00 a.m.-8:00 a.m.  BREAKFAST  
Grand Ballroom BC

8:00 a.m.-10:00 a.m.  PLENARY SESSION 5: CELLULAR THERAPY CLINICAL UPDATES (II)  
Grand Ballroom A  
Session Chair: Sattva S. Neelapu, The University of Texas MD Anderson Cancer Center, Houston, TX

8:00 a.m.-8:30 a.m.  CAR T-cell therapy for lymphomas: Current and future strategies  
Sattva S. Neelapu

8:30 a.m.-9:00 a.m.  Expanding CAR T-cell therapy to a wide spectrum of pediatric malignancies  
Julie R. Park, Seattle Children's Hospital, Seattle, WA

9:00 a.m.-9:30 a.m.  Addressing relapse associated with leukemic resistance to CAR T cells  
Terry J. Fry, University of Colorado Denver Children's Hospital Colorado, Aurora, CO

9:30 a.m.-9:45 a.m.  Predicting CD19Neg relapse following CAR T-cell therapy in B-cell precursor acute lymphoblastic leukemia*  
Pablo Domizi, Stanford University School of Medicine, Stanford, CA

9:45 a.m.-10:00 a.m.  Phase I adoptive cellular therapy trial with endogenous CD8+ T cells (ACTolog IMA101) in patients with relapsed and/or refractory solid cancers*  
Harpreet Singh, Immatics US, Inc., Houston, TX

10:00 a.m.-10:30 a.m.  BREAK  
Grand Ballroom Foyer

10:30 a.m.-12:15 p.m.  PLENARY SESSION 6: OPTIMIZATION OF TARGET ANTIGENS FOR TCR AND TIL  
Grand Ballroom A  
Session Chair: Alex Franzusoff, PACT Pharma, Inc., South San Francisco, CA

10:30 a.m.-11:00 a.m.  Novel naturally presented targets for personalized T-cell therapies  
Harpreet Singh, Immatics US, Inc., Houston, TX

11:00 a.m.-11:30 a.m.  Personalized neoantigen-targeting adoptive TCR-T cell therapies for solid tumors  
Alex Franzusoff
2019 AACR Special Conference on Immune Cell Therapies for Cancer: Successes and Challenges of CAR T Cells and Other Forms of Adoptive Therapy

11:30 a.m.-11:45 p.m.  
**Personalized gene editing of T cells to express neoantigen-specific TCRs isolated from peripheral blood of patients on PD-1 blockade therapy**
Cristina Puig-Saus, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA

11:45 a.m.-12:00 p.m.  
**Finding CAR-T drivers for GBM: Building a translational discovery pipeline**
Sheila Kumari Singh, McMaster University Medical Center, Hamilton, ON, Canada

12:00 p.m.-12:15 p.m.  
**Immunopeptidomics and peptide expression profiles to develop T-cell receptors against glioma-associated antigens**
Diego A. Carrera, University of California San Francisco School of Medicine, San Francisco, CA

12:15 p.m.-2:30 p.m.  
**LUNCH ON OWN**

2:30 p.m.-4:30 p.m.  
**PLENARY SESSION 7: COMBINATION THERAPY WITH ADOPTIVE CELL THERAPY**  
Grand Ballroom A  
**Session Chair: Ivan M. Borrello**, Johns Hopkins University, Baltimore, MD

2:30 p.m.-3:00 p.m.  
**Unveiling mechanisms of response and resistance to instruct next-generation cancer immunotherapy**
Aude G. Chapuis, Fred Hutchinson Cancer Research Center, Seattle, WA

3:00 p.m.-3:30 p.m.  
**Marrow-infiltrating lymphocytes; Biology and practice**  
Ivan M. Borrello

3:30 p.m.-4:00 p.m.  
**Combining checkpoint blockade with CAR T-cell therapy to augment response**
Shannon L. Maude, Children’s Hospital of Philadelphia, Philadelphia, PA

4:00 p.m.-4:15 p.m.  
**Conditioning treatment with a CD27 antibody enhances in vivo expansion and antitumor activity of adoptively transferred T cells**  
Li-Zhen He, Celldex Therapeutics, Inc., Hampton, NJ

4:15 p.m.-4:30 p.m.  
**IL-2 limits CAR T-cell efficacy through selective expansion of a differentiated and less functional subset marked by the loss of CD27 expression**
Dongrui Wang, City of Hope National Medical Center, Duarte, CA
2019 AACR Special Conference on Immune Cell Therapies for Cancer: Successes and Challenges of CAR T Cells and Other Forms of Adoptive Therapy

4:30 p.m.-6:30 p.m. RECEPTION / POSTER SESSION B
Grand Ballroom BC

Monday, July 22

7:00 a.m.-8:00 a.m. BREAKFAST
Grand Ballroom BC

8:00 a.m.-10:00 a.m. PLENARY SESSION 8: ENHANCING IMMUNE CELL FUNCTION THROUGH GENETIC ENGINEERING
Grand Ballroom A
Session Chair: Rodabe N. Amaria, The University of Texas MD Anderson Cancer Center, Houston, TX

8:00 a.m.-8:30 a.m. Tumor-infiltrating lymphocyte therapy for metastatic melanoma
Rodabe N. Amaria

8:30 a.m.-9:00 a.m. Enhancing CAR T-cell therapy by enabling CAR T-cell interaction with antigen-presenting cells
Clare Y. Slaney, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

9:00 a.m.-9:30 a.m. Strategies to improve CAR T persistence and solid tumor targeting
Avery D. Posey, Jr., University of Pennsylvania, Philadelphia, PA

9:30 a.m.-9:45 a.m. Convertible CAR-T cells provide a highly modular universal system for dose control of activity, targeting flexibility, and in vivo CAR maintenance*
Kaman Kim, Xyphos Biosciences, San Francisco, CA

9:45 a.m.-10:00 a.m. Adapter CAR T cells (AdCAR-T) allow precise control on effector function, prevent antigen evasion, and enable differential target cell lysis, based on complex antigen expression profiles*
Christian M. Seitz, University Children's Hospital Tübingen, Tübingen, Germany

10:00 a.m.-10:30 a.m. BREAK
Grand Ballroom Foyer

10:30 a.m.-12:00 p.m. PLENARY SESSION 9: NOVEL APPROACHES FOR GENE DELIVERY (ENGINEERED VECTORS AND VIRAL DELIVERY SYSTEMS)
Grand Ballroom A
2019 AACR Special Conference on Immune Cell Therapies for Cancer: Successes and Challenges of CAR T Cells and Other Forms of Adoptive Therapy

Session Chair: Laurence Cooper, Ziopharm Oncology, Boston, MA

10:30 a.m.-11:00 a.m.  T cells genetically modified using nonviral gene transfer to target cancer
                        Laurence Cooper

11:00 a.m.-11:30 a.m.  Reprogramming human immune cell circuitry
                        Alexander Marson, University of California San Francisco, San Francisco, CA

11:30 a.m.-12:00 p.m.  Engineering smarter and stronger T cells for cancer immunotherapy
                        Yvonne Y. Chen, University of California Los Angeles, Los Angeles, CA

12:00 p.m.  CONCLUSION

*Short talk from proffered abstract